Lipid mesophase technology for controlled biologic delivery in skin regeneration
Advanced lipid mesophase technology enhances plasminogen delivery for accelerated wound healing by protecting stability, enhancing cellular delivery, and enabling microenvironment-responsive release.
Overview
This innovative lipid mesophase technology is designed to optimize the delivery of plasminogen, a promising biologic for wound healing and skin regeneration. By addressing current delivery and dosing challenges, the technology enhances plasminogen stability, facilitates cellular fusion, and allows for tunable, microenvironment-responsive drug release. This platform represents a significant advancement in regenerative medicine by providing precise control over biologic delivery and activity at injury sites.
Technical specifications
Key features:
- Protection of plasminogen stability: Encapsulation within lipid mesophases maintains therapeutic concentrations.
- Enhanced cellular delivery: Facilitates cellular fusion and intracellular delivery for improved therapeutic outcomes.
- Tunable release: Enables microenvironment-responsive release, adapting to the needs of the injury site.
- Versatile applications: Includes mesophase-coated occlusive dressings and microneedle delivery systems for targeted treatment.
Applications:
- Mesophase-coated occlusive dressings for enhanced wound healing.
- Plasminogen protection and controlled release for regenerative medicine.
- Microneedle delivery systems for precise application to dark spots and scars.
Technology readiness level
This technology is at Technology Readiness Level 3. It is currently in the experimental proof of concept stage, with ongoing development focused on characterizing nanoscale features, biologic stability, and release profiles through various preclinical studies.
About Monash University, Melbourne
Monash University is a comprehensive public research university and one of Australia’s largest, known for scale, interdisciplinarity, and an applied orientation. Its Melbourne-based technology precinct brings together university laboratories, pilot-scale and prototyping suites, and company R&D groups alongside government research organizations to enable co-development and rapid iteration. Integration with a major hospital network supports clinical trials and translation, while structured industry placements and doctoral partnerships create a robust talent pipeline for corporate R&D. Research is backed by competitive funding from the Australian Research Council, the National Health and Medical Research Council, and state and federal programs that incentivize industry collaboration. A dedicated technology transfer office manages IP, licensing, and startup formation, with pathways to incubation and investment within the precinct.
Inquire about this partnering listing
Industry applications
delivered to your inbox.